Standard BioTools (LAB) Projected to Announce Quarterly Earnings on Wednesday

Standard BioTools (NASDAQ:LAB) is projected to release its Q2 2026 results after the market closes on Wednesday, August 5th. Analysts expect Standard BioTools to announce earnings of ($0.01) per share and revenue of $20.8040 million for the quarter. Parties can check the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Monday, August 10, 2026 at 4:30 PM ET.

Standard BioTools Trading Down 2.1%

Shares of NASDAQ LAB opened at $0.85 on Monday. Standard BioTools has a twelve month low of $0.70 and a twelve month high of $1.72. The stock has a 50 day moving average of $0.90 and a two-hundred day moving average of $1.03. The stock has a market cap of $331.85 million, a P/E ratio of 4.25 and a beta of 1.39.

Hedge Funds Weigh In On Standard BioTools

Several institutional investors have recently bought and sold shares of the company. Cibc World Markets Corp purchased a new position in Standard BioTools during the 4th quarter worth $25,000. Aigen Investment Management LP acquired a new position in shares of Standard BioTools during the fourth quarter worth about $28,000. EntryPoint Capital LLC acquired a new position in shares of Standard BioTools during the fourth quarter worth about $31,000. CIBC Asset Management Inc purchased a new position in Standard BioTools during the fourth quarter worth about $33,000. Finally, Russell Investments Group Ltd. raised its holdings in Standard BioTools by 2,989.0% during the third quarter. Russell Investments Group Ltd. now owns 25,021 shares of the company’s stock worth $33,000 after purchasing an additional 24,211 shares in the last quarter. 53.74% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings raised shares of Standard BioTools from a “sell (d)” rating to a “sell (d+)” rating in a report on Tuesday, July 21st. Two equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Standard BioTools presently has an average rating of “Reduce” and an average price target of $1.35.

Standard BioTools Company Profile

Standard BioTools, Inc (NASDAQ: LAB), formerly known as Fluidigm Corporation, is a life sciences tools company that develops and commercializes high-parameter, single-cell and spatial biology solutions. The company’s platforms integrate microfluidics, mass cytometry, sequencing and imaging to enable researchers to probe cellular heterogeneity, molecular interactions and complex tissue architecture. Its end users span academic institutions, pharmaceutical and biotechnology companies worldwide.

The company’s flagship products include mass cytometry systems—such as the Helios and Hyperion Imaging System—for multiplexed protein analysis at single-cell resolution, and the Chromium-style single-cell genomic tools for high-throughput gene expression profiling.